Related Experiment Video
Updated: Jul 31, 2026
10:49
Antibiotic Dereplication Using the Antibiotic Resistance Platform
Published on: October 17, 2019
Why are there no new antibiotics?
Expert Opinion on Investigational Drugs
|July 5, 2005
Summary
The pharmaceutical industry is renewing efforts to combat antibiotic-resistant pathogens by developing new discovery tools. These advancements aim to identify key targets in bacterial metabolism for novel antibiotic development.
Area of Science:
- Microbiology
- Pharmacology
- Biochemistry
Background:
- The rise of antibiotic-resistant pathogens presents a significant global health challenge.
- Traditional antibiotic discovery pipelines face limitations in addressing novel resistance mechanisms.
Discussion:
- Novel tools and technologies are crucial for understanding bacterial metabolic pathways.
- Identifying critical therapeutic intervention points can guide the development of effective antimicrobial agents.
- Interdisciplinary approaches combining genomics, metabolomics, and drug discovery are essential.
Key Insights:
- Pharmaceutical companies are reinvesting in antibiotic research and development.
- Advanced technologies are being utilized to explore bacterial metabolism for drug targets.
- Focus is shifting towards understanding the metabolic vulnerabilities of resistant bacteria.
Outlook:
- Continued innovation in discovery platforms will accelerate the identification of new antibiotic candidates.
- Targeting bacterial metabolism offers a promising strategy to overcome existing resistance.
- Collaborative efforts between academia and industry are vital for future success in combating antimicrobial resistance.
Related Concept Videos
00:57Antibiotic Selection
Overview
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
01:21Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...